Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
2.6
Journals
Medicina
Special Issues
Current Trends in Otorhinolaryngology and Head and Neck Pathology: 2nd...
share announcement

Current Trends in Otorhinolaryngology and Head and Neck Pathology: 2nd Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Surgery".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2873

Special Issue Editors

Prof. Dr. Codrut Sarafoleanu

E-Mail Website
Guest Editor
ENT Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Interests: imaging; allergy; rhinology and skullbase; treatment of ENT pathology; interdisciplinary management into current practice; implants in ENT and head and neck pathology; sleep medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Daniela Vrinceanu

E-Mail Website
Guest Editor
ENT Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Interests: oncology—head and neck surgery; artificial intelligence; interdisciplinary management into current practice; rhinology; allergy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Mahmut Tayyar Kalcioglu

E-Mail Website
Guest Editor
Chief of the Department of ORL & HNS, Istanbul Medeniyet University, Istanbul, Turkey
Interests: ENT pathology treatment; imaging ENT; sleep apnea; allergy; implants in ENT and head and neck pathology; artificial intelligence; cochlear implant; ear surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Adriana Neagos

E-Mail Website
Guest Editor
ENT Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Tirgu Mures, Romania
Interests: ENT pathology; imaging modalities; sleep apnea and quality of life; allergic reactions; implants in ENT and head and neck pathology; cochlear implants; ear surgery; artificial intelligence; translation of interdisciplinary management into current practice
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are grateful to you for submitting your valuable original articles to the previous Special Issue, ‘Current Trends in Otorhinolaryngology and Head and Neck Pathology’, which undeniably benefited the research community. In light of this success, we now present you the second edition of this Special Issue.

The incidence and prevalence rate of various pathologies of otorhinolaryngology and head and neck-related issues worldwide have increased substantially, with many of the conditions’ development being overlooked during the COVID-19 pandemics. In recent years, new directions in this medical branch have emerged, such as surgery of the skull base and infratemporal fossa, neuronavigation systems in rhinosinusal endoscopic surgery, new techniques of neck dissection that takes into account the cervical lymph nodes’ role in the immune system, modified protocols in HPV-positive cancer of head and neck, the use of biologics in chronic rhinosinusitis with nasal polyposis, electric hypoglossal stimulation in sleep apnea syndrome, and new advancements in cochlear implantation. Additionally, artificial intelligence systems are also being integrated into treatments to prevent the risks in head and neck surgery, thereby proving that an interdisciplinary approach is the key to solve complex cases.

In this Special Issue, we welcome submissions of manuscripts, including original articles, reviews and selected rare case series, reflecting the current trends and new directions in otorhinolaryngology and head and neck surgery. We hope this will increase the knowledge on the numerous pathologies that contribute to the high complexity of ENT&HNS and help to update the protocols and connect specialties worldwide in the aftermath of the COVID-19 pandemic.

Prof. Dr. Codrut Sarafoleanu
Dr. Daniela Vrinceanu
Prof. Dr. Mahmut Tayyar Kalcioglu
Dr. Adriana Neagos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • otorhinolaryngology
  • head neck
  • pathology
  • imaging
  • surgery
  • treatment
  • oncology
  • apnea
  • allergy
  • artificial intelligence
  • interdisciplinary
  • ear
  • cochlear implant

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1644 KiB  
Article
The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye
by Meryem Demir, Ceyda Tunakan Dalgic, Emine Nihal Mete Gokmen, Recep Savas, Suleyman Eroglu, Guzin Ozden, Cihan Orcen, Gulden Pacaci Cetin, Bahar Arslan, Ferda Bilgir, Gokten Bulut, Nurullah Yekta Akcam, Semiha Ozgul, Pamir Cerci, Raif Coskun, Sercan Gode, Insu Yilmaz and Aytul Zerrin Sin
Medicina 2024, 60(3), 448; https://doi.org/10.3390/medicina60030448 - 08 Mar 2024
Viewed by 758
Abstract
Background and Objectives: Real-life data on the efficacy of biologic agents (BAs) on asthma-comorbid CRSwNP are needed. Our primary goal is to investigate the effects of BAs on CRSwNP symptoms, as well as endoscopic and tomography scores. Our secondary goal is to [...] Read more.
Background and Objectives: Real-life data on the efficacy of biologic agents (BAs) on asthma-comorbid CRSwNP are needed. Our primary goal is to investigate the effects of BAs on CRSwNP symptoms, as well as endoscopic and tomography scores. Our secondary goal is to show a reduction in the frequency of acute sinusitis exacerbations and the need for surgery. Materials and Methods: We conducted a multicenter, retrospective, real-life study. We screened the patients with asthma-comorbid CRSwNP treated with omalizumab or mepolizumab. A total of 69 patients (40 F/29 M; omalizumab n = 55, mepolizumab n = 14) were enrolled. We compared the visual analog scale (VAS), sinonasal outcome test-22 (SNOT-22), nasal congestion score (NCS), Lund–Mackay computed tomography score (LMS), and total endoscopic polyp scores (TPS) before and after BAs. We evaluated the endoscopic sinus surgery (ESS) and acute exacerbations of chronic rhinosinusitis (AECRS) frequencies separately, according to the BAs. Results: The overall median (min–max) age was 43 (21–69) years. The median (min–max) of biologic therapy duration was 35 (4–113) months for omalizumab and 13.5 (6–32) for mepolizumab. Significant improvements were seen in VAS, SNOT-22, and NCS with omalizumab and mepolizumab. A significant decrease was observed in TPS with omalizumab [95% CI: 0–4] (p < 0.001), but not with mepolizumab [95% CI: −0.5–2] (p = 0.335). The frequency of ESS and AECRS were significantly reduced with omalizumab [95% CI: 2–3] (p < 0.001) and [95% CI: 2–5] (p < 0.001); and mepolizumab [95% CI: 0–2] (p = 0.002) and [95% CI: 2–8.5] (p < 0.001), respectively. There was no significant difference in LMS with either of the BAs. Conclusions: Omalizumab and mepolizumab can provide a significant improvement in the sinonasal symptom scores. BAs are promising agents for CRSwNP patients with frequent exacerbations and multiple surgeries. Full article
(This article belongs to the Special Issue Current Trends in Otorhinolaryngology and Head and Neck Pathology: 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 339 KiB  
Review
Comorbidities and Laryngeal Cancer in Patients with Obstructive Sleep Apnea: A Review
by Beata Kiss, Cristian Mircea Neagos, Gabriela Jimborean, Hédi Katalin Sárközi, Mioara Szathmary and Adriana Neagos
Medicina 2023, 59(11), 1959; https://doi.org/10.3390/medicina59111959 - 06 Nov 2023
Viewed by 1679
Abstract
Introductions: The global prevalence of obstructive sleep apnea shows that this disease appears in 1 billion people, with the prevalence exceeding 50% in some countries. Treatment is necessary to minimize negative health impacts. Obstructive sleep apnea (OSA) is defined as a cause [...] Read more.
Introductions: The global prevalence of obstructive sleep apnea shows that this disease appears in 1 billion people, with the prevalence exceeding 50% in some countries. Treatment is necessary to minimize negative health impacts. Obstructive sleep apnea (OSA) is defined as a cause of daytime sleepiness, as well as a clinical manifestation of sleep-disordered breathing. In the literature, there are numerous controversial studies regarding the etiology of this condition, but it is universally accepted that reduced activity in the upper airway muscles plays a significant role in its onset. Additionally, OSA has been associated with a series of comorbidities, such as type II diabetes, metabolic syndrome, and cardiovascular and pulmonary conditions, as well as head and neck tumors, especially oropharyngeal and laryngeal tumors. This is a review of the subject of OSA that considers several aspects: an analysis of the comorbidities associated with OSA, the involvement of tumor pathology in the onset of OSA, and the association of OSA with various types of laryngeal cancers. Additionally, it includes an evaluation of postoperative and medical outcomes for patients with OSA and laryngeal tumors treated surgically and medically, including chemotherapy. Relevant Sections: By taking into consideration the stated objective, a systematic analysis of the available literature was conducted, encompassing the PubMed, Medline, and Scopus databases. The evaluation was based on several keywords, including head and neck cancer, diabetes, diabetic, overlap syndrome, cardiovascular conditions, laryngeal neoplasm, radiotherapy, and chemotherapy, as well as the concept of quality of life in laryngectomized patients and patients with OSA. Discussions: The review evaluates the involvement of OSA in the presence of comorbidities, as well as the increased incidence of OSA in patients with laryngeal cancer. It is important to note that surgical and post-surgical treatment can play a significant role in triggering OSA in these patients. Conclusions: The studies regarding the correlations between OSA, comorbidities, and head and neck tumors indicate a significantly increased risk of OSA in association with conditions such as diabetes, metabolic syndrome, cardiovascular diseases, and head and neck tumors, particularly laryngeal tumors. This association has a physio-pathological basis. The various surgical methods followed by radiation and chemotherapy for tumor treatment do not exclude an increased risk of developing OSA after treatment. This significantly influences the quality of life of patients who survive these types of tumors. Future directions: Due to the multiple comorbidities associated with OSA, the extension of polysomnography associated with investigations during sleep, such as drug-induced sleep endoscopy, represents a tendency for the early diagnosis of this pathology, which affects the quality of life of these patients. Patients with head and neck cancer are at high risk of developing obstructive sleep apnea; this is why it is necessary to expand the polysomnographic investigation of these patients after surgical procedures or after radiotherapy and chemotherapy. Full article
(This article belongs to the Special Issue Current Trends in Otorhinolaryngology and Head and Neck Pathology: 2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop